Leishmania is a terrible disease transmitted by the bite of a sandfly. Tackling it has been given priority by the WHO, especially as co-infection with HIV has been identified. Many current treatments are costly, have serious side effects and more worryingly drug resistance has been reported even in the most recent drugs. Therefore identifying new therapeutic targets to combat this disease is imperative.
Patrick Steel and a team from Durham University have targeted the membrane bound enzyme inositol phosphorylceramide synthase (IPCS) – which is essential for the survival of Leishmania species. They synthesised a series of ceramide analogues, changing the sphingosine tail, N-acyl unit and the degree of hydroxylation to explore the enzyme active site. The analogues were assayed against Leishmania major IPCS to determine the degree of inhibition and a mechanism of action was subsequently proposed.
Read about their findings here – the article is free to access for 4 weeks:
Exploring Leishmania major Inositol Phosphorylceramide Synthase (LmjIPCS): Insights into the ceramide binding domain
John G. Mina, Jackie A. Mosely, Hayder Z. Ali, Paul W. Denny and Patrick G. Steel
Org. Biomol. Chem., 2011, Advance Article
DOI: 10.1039/C0OB00871K